Heparin thromboprophylaxis in medical-surgical critically ill patients: A systematic review and meta-analysis of randomized trials

Critical Care Medicine

Volumn 41, Issue 9, 2013, Pages 2088-2098

  Alhazzani, Waleed ^a   Lim, Wendy ^a   Jaeschke, Roman Z ^a   Murad, Mohammad Hassan ^b   Cade, Jack ^c   Cook, Deborah J ^a  

^a MCMASTER UNIVERSITY   (Canada)

^b MAYO CLINIC   (United States)

^c ROYAL MELBOURNE HOSPITAL   (Australia)

Author keywords

bleeding; critical illness; deep vein thrombosis; heparin; pulmonary embolism; venous thromboembolism

Indexed keywords

DALTEPARIN; DROTRECOGIN; ENOXAPARIN; HEPARIN; LOW MOLECULAR WEIGHT HEPARIN; NADROPARIN; PLACEBO;

CRITICALLY ILL PATIENT; DEEP VEIN THROMBOSIS; DRUG EFFICACY; DRUG SAFETY; HEPARIN INDUCED THROMBOCYTOPENIA; HUMAN; INTENSIVE CARE UNIT; LUNG EMBOLISM; META ANALYSIS; MORTALITY; PRIORITY JOURNAL; PROPHYLAXIS; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; RISK FACTOR; SEPSIS; SURGICAL PATIENT; SYSTEMATIC REVIEW; TREATMENT OUTCOME;

ANTICOAGULANTS; CRITICAL ILLNESS; HEPARIN, LOW-MOLECULAR-WEIGHT; HOSPITALIZATION; HUMANS; INTENSIVE CARE UNITS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; TREATMENT OUTCOME; VENOUS THROMBOSIS;

EID: 84883653401     PISSN: 00903493     EISSN: 15300293     Source Type: Journal    
DOI: 10.1097/CCM.0b013e31828cf104     Document Type: Review

References (42)

1. Dentali F, Douketis JD, Gianni M, et al: Meta-analysis: Anticoagulant prophylaxis to prevent symptomatic venous thromboembolism in hospitalized medical patients. Ann Intern Med 2007; 146:278-288
2. Lederle FA, Zylla D, MacDonald R, et al: Venous thromboembolism prophylaxis in hospitalized medical patients and those with stroke: A background review for an American College of Physicians Clinical Practice Guideline. Ann Intern Med 2011; 155:602-615
3. Mismetti P, Laporte S, Darmon JY, et al: Meta-analysis of low molecular weight heparin in the prevention of venous thromboembolism in general surgery. Br J Surg 2001; 88:913-930
4. Hirsch DR, Ingenito EP, Goldhaber SZ: Prevalence of deep venous thrombosis among patients in medical intensive care. JAMA 1995; 274:335-337
5. Moser KM, LeMoine JR, Nachtwey FJ, et al: Deep venous thrombosis and pulmonary embolism. Frequency in a respiratory intensive care unit. JAMA 1981; 246:1422-1424
6. Arnold DM, Donahoe L, Clarke FJ, et al: Bleeding during critical illness: A prospective cohort study using a new measurement tool. Clin Invest Med 2007; 30:E93-102
7. Geerts W, Cook D, Selby R, et al: Venous thromboembolism and its prevention in critical care. J Crit Care 2002; 17:95-104
8. Ribic C, Lim W, Cook D, et al: Low-molecular-weight heparin thromboprophylaxis in medical-surgical critically ill patients: A systematic review. J Crit Care 2009; 24:197-205
9. Cade JF: High risk of the critically ill for venous thromboembolism. Crit Care Med 1982; 10:448-450
10. Attia J, Ray JG, Cook DJ, et al: Deep vein thrombosis and its prevention in critically ill adults. Arch Intern Med 2001; 161:1268-1279
11. Goldhaber SZ: Venous thromboembolism in the intensive care unit: The last frontier for prophylaxis. Chest 1998; 113:5-7
12. Fraisse F, Holzapfel L, Couland JM, et al: Nadroparin in the prevention of deep vein thrombosis in acute decompensated COPD. The Association of Non-University Affiliated Intensive Care Specialist Physicians of France. Am J Respir Crit Care Med 2000; 161(4 Part 1):1109-1114
13. De A, Roy P, Garg VK, et al: Low-molecular-weight heparin and unfractionated heparin in prophylaxis against deep vein thrombosis in critically ill patients undergoing major surgery. Blood Coagul Fibrinolysis 2010; 21:57-61
14. Shorr AF, Williams MD: Venous thromboembolism in critically ill patients. Observations from a randomized trial in sepsis. Thromb Haemost 2009; 101:139-144
15. PROTECT Investigators. Writing Committee; Cook D, Meade M, Guyatt G, et al: Dalteparin versus unfractionated heparin in critically ill patients. N Engl J Med 2011; 364:1305-1314
16. Kakkos SK, Caprini JA, Geroulakos G, et al: Combined intermittent pneumatic leg compression and pharmacological prophylaxis for prevention of venous thromboembolism in high-risk patients. Cochrane Database Syst Rev 2008;(4) CD005258
17. Limpus A, Chaboyer W, McDonald E, et al: Mechanical thromboprophylaxis in critically ill patients: A systematic review and meta-analysis. Am J Crit Care 2006; 15:402-410
18. Higgins JP, Altman DG, Gøtzsche PC, et al; Cochrane Bias Methods Group; Cochrane Statistical Methods Group: The Cochrane Collaboration's tool for assessing risk of bias in randomised trials. BMJ 2011; 343:d5928
19. Guyatt GH, Oxman AD, Vist GE, et al; GRADE Working Group: GRADE: An emerging consensus on rating quality of evidence and strength of recommendations. BMJ 2008; 336:924-926
20. Deeks J, Higgins J, Altman D: Analyzing data and undertaking meta-analyses. In: Cochrane Handbook for Systematic Reviews of Interventions Version 5.0.0. Higgins J, Green S (Eds). Cochrane Collaboration and John Wiley & Sons, Ltd, the Atrium, South Gate, Chichester, West Sussex, 2008, pp 297-334
21. Borenstein M, Hedges LV, Higgins JPT, et al (Eds): Fixed-effect versus random-effect models. In: Introduction to Meta-Analysis. Chichester, UK, John Wiley & Sons Limited, 2009, pp 77-85
22. Kapoor M, Kupfer YY, Tessler S: Subcutaneous heparin prophylaxis significantly reduces the incidence of venous thromboembolic events in the critically ill. Abstr. Crit Care Med 1999; 27(Suppl):A69
23. Goldhaber SZ, Kett DH, Cusumano CJ, et al: Low molecular weight heparin versus minidose unfractionated heparin for prophylaxis against venous thromboembolism in medical intensive care unit patients: A randomized controlled trial. Abstr. J Am Coll Cardiol 2000; 35(Suppl):325A
24. Levi M, Levy M, Williams MD, et al; Xigris and Prophylactic HepaRin Evaluation in Severe Sepsis (XPRESS) Study Group: Prophylactic heparin in patients with severe sepsis treated with drotrecogin alfa (activated). Am J Respir Crit Care Med 2007; 176:483-490
25. Kupfer Y, Anwar J, Senenviratne C, et al: Prophylaxis with subcutaneous heparin significantly reduces the incidence of deep vein thrombosis in the critically ill. Am J Resp Crit Care Med 1999; 159(Suppl):A519
26. Sterne JAC, Egger M, Moher D: Chapter 10: Addressing reporting biases. In: Cochrane Handbook for Systematic Reviews of Interventions. Higgins JPT, Green S (Eds). Chichester, UK, John Wiley & Sons, 2008
27. Phung OJ, Susan R, Kahn S, et al: Unfractionated heparin thromboprophylaxis dosing frequency. Chest 2011; 140:374-381
28. Warwick D, Samama MM: The contrast between venographic and clinical endpoints in trials of thromboprophylaxis in hip replacement. J Bone Joint Surg Br 2000; 82:480-482
29. Geerts WH, Heit JA, Clagett GP, et al: Prevention of venous thromboembolism. Chest 2001; 119(1 Suppl):132S-175S
30. Crowther MA, Cook DJ, Griffith LE, et al: Deep venous thrombosis: Clinically silent in the intensive care unit. J Crit Care 2005; 20:334-340
31. Cook D, Meade M, Guyatt G, et al; Canadian Critical Care Trials Group: Clinically important deep vein thrombosis in the intensive care unit: A survey of intensivists. Crit Care 2004; 8:R145-R152
32. Fareed J, Jeske W, Fareed D, et al: Are all low molecular weight heparins equivalent in the management of venous thromboembolism? Clin Appl Thromb Hemost 2008; 14:385-392
33. Prandoni P: Low molecular weight heparins: Are they interchangeable? Yes. J Thromb Haemost 2003; 1:10-11
34. Nenci GG: Low molecular weight heparins: Are they interchangeable? No. J Thromb Haemost 2003; 1:12-13
35. van der Heijden JF, Prins MH, Büller HR: Low-molecular-weight heparins: Are they interchangeable? Haemostasis 2000; 30(Suppl 2):148-157; discussion 146
36. Douketis J, Cook DJ, Meade M, et al for the Canadian Critical Care Trials Group: Renal insuffiency with the low-molecular-weight heparin dalteparin: An assessment of safety and pharmacodynamics. The DIRECT (Dalteparin's Influence on REnally Compromised anti-Ten-A) Study. Arch Intern Med 2008; 168:1805-1812
37. McAlister F, Laupacis A, Wells G: Drug class effects. In: Users' Guide to the Medical Literature: A Manual for Evidence-Based Practice. Guyatt GH, Meade MO, Rennie D, et al (Eds). Burr Ridge, IL, McGraw-Hill, 2008, pp 703-716
38. Guyatt GH, Norris SL, Schulman S, et al; American College of Chest Physicians: Methodology for the development of antithrombotic therapy and prevention of thrombosis guidelines: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 2012; 141(2 Suppl):53S-70S
39. Pogue JM, Yusuf S: Cumulating evidence from randomized trials: Utilizing sequential monitoring boundaries for cumulative meta-analysis. Control Clin Trials 1997; 18:580-593
40. Dennis M, Sandercock PA, Reid J, et al: Effectiveness of thigh-length graduated compression stockings to reduce the risk of deep vein thrombosis after stroke (CLOTS trial 1): A multicentre, randomised controlled trial. Lancet 2009; 373:1958-1965
41. CLOTS Trial Collaboration: CLOTS-2. Thigh-length versus belowknee stockings for deep venous thrombosis prophylaxis after stroke: A randomized trial. Ann Intern Med 2010; 153:553-562
42. Koch A, Ziegler S, Breitschwerdt H, et al: Low molecular weight heparin and unfractionated heparin in thrombosis prophylaxis: Meta-analysis based on original patient data. Thromb Res 2001; 102:295-309